1. Home
  2. IMUX vs PGP Comparison

IMUX vs PGP Comparison

Compare IMUX & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

SELL

Current Price

$7.24

Market Cap

100.2M

Sector

Health Care

ML Signal

SELL

Logo Pimco Global StocksPlus & Income Fund of Beneficial Interest

PGP

Pimco Global StocksPlus & Income Fund of Beneficial Interest

SELL

Current Price

$7.96

Market Cap

93.8M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
IMUX
PGP
Founded
2016
2003
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
100.2M
93.8M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
IMUX
PGP
Price
$7.24
$7.96
Analyst Decision
Strong Buy
Analyst Count
13
0
Target Price
★ $42.64
N/A
AVG Volume (30 Days)
★ 248.3K
43.2K
Earning Date
11-13-2026
01-01-0001
Dividend Yield
N/A
★ 10.84%
EPS Growth
★ 38.00
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$7.95
52 Week High
$17.43
$9.41

Technical Indicators

Market Signals
Indicator
IMUX
PGP
Relative Strength Index (RSI) 40.86 38.64
Support Level $6.35 N/A
Resistance Level $8.41 $8.87
Average True Range (ATR) 0.55 0.15
MACD 0.11 -0.00
Stochastic Oscillator 11.81 4.35

Price Performance

Historical Comparison
IMUX
PGP

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, as well as long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

Share on Social Networks: